Melissa Hardesty, MD, MPH, Discusses the Focus of the 2021 Society of Gynecologic Oncology Annual Meeting
Hardesty detailed her expectations for the focus of the conference and the exciting topical opportunities presented this year’s SGO Annual Meeting compared with past years.
Melissa Hardesty, MD, MPH, of the Alaska Women’s Cancer Care, spoke with CancerNetwork® regarding topics of discussion at the forefront of this year’s Society of Gynecologic Oncology (SGO) 2021 Annual Meeting on Women’s Cancer.
Transcription:
This year, the meeting has focused on diversity and inclusiveness [by] really looking at some actual research about how these things impact our patients, how they impact our providers, racial bias, and all of that. There’s a lot of content that’s specifically trying to help us learn how to do better in these ways, to just continue on further conversations. I know that the program organizers have put a strong emphasis on that. There [are] exciting talks in the opening plenary that I think in meetings past might not have been selected for [presentation, and] focusing on the commitment to that area.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
![A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F6b7c9a3270c71a70749ba86000cfc78a29d74309-2988x1702.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.")
![We have the current CAR [T-cell therapies], which target CD19; however, we need others.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F6d5ddb2c2098f525a65b378ece6ca55a114f95fc-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "We have the current CAR [T-cell therapies], which target CD19; however, we need others.")
